Symptoms of HMPV usually overlap with those of other respiratory viruses and can include cough, fever, nasal congestion, and shortness of breath. More severe infections can lead to bronchitis, ...
March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce ...
Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical lifespan. What it often takes to achieve that level of longevity, however, is ...
Victoria’s Labor government had signalled it was expecting to spend $40 million defending the suit brought by more than 1000 ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through ...
The US has already reported more than 1,100 measles cases in the first two months of 2026 — six times more than has been ...
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results